{"product_id":"new-product-633792","title":"ELISA Kit for Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9)","description":"\u003cp\u003eEnzyme-linked immunosorbent assay for Antigen Detection.\u003c\/p\u003e\n\u003cp\u003eProduct No.\u003c\/p\u003e\n\u003cp\u003eSEE189Rb\u003c\/p\u003e\n\u003cp\u003eOrganism Species\u003c\/p\u003e\n\u003cp\u003eOryctolagus cuniculus (Rabbit).\u003c\/p\u003e\n\u003cp\u003eSample Type\u003c\/p\u003e\n\u003cp\u003eSerum, plasma, tissue homogenates and other biological fluids\u003c\/p\u003e\n\u003cp\u003eTest Method\u003c\/p\u003e\n\u003cp\u003eDouble-antibody Sandwich\u003c\/p\u003e\n\u003cp\u003eAssay Length\u003c\/p\u003e\n\u003cp\u003e3h\u003c\/p\u003e\n\u003cp\u003eDetection Range\u003c\/p\u003e\n\u003cp\u003e0.312-20ng\/mL\u003c\/p\u003e\n\u003cp\u003eSensitivity\u003c\/p\u003e\n\u003cp\u003eThe minimum detectable dose of this kit is typically less than 0.114ng\/mL.\u003c\/p\u003e\n\u003cp\u003eUOM\u003c\/p\u003e\n\u003cp\u003e48T 96T 96T*5 96T*10 96T*100\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eSpecificity\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThis assay has high sensitivity and excellent specificity for detection of Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9).\u003cbr\u003eNo significant cross-reactivity or interference between Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) and analogues was observed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eRecovery\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eMatrices listed below were spiked with certain level of recombinant Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) and the recovery rates were calculated by comparing the measured value to the expected amount of Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) in samples.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003eRecovery range (%)\u003c\/td\u003e\n\u003ctd\u003eAverage(%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eserum(n=5)\u003c\/td\u003e\n\u003ctd\u003e85-97\u003c\/td\u003e\n\u003ctd\u003e92\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDTA plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e91-101\u003c\/td\u003e\n\u003ctd\u003e95\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eheparin plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e94-101\u003c\/td\u003e\n\u003ctd\u003e97\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3\u003ePrecision\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) were tested 20 times on one plate, respectively.\u003cbr\u003eInter-assay Precision (Precision between assays): 3 samples with low, middle and high level Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) were tested on 3 different plates, 8 replicates in each plate.\u003cbr\u003eCV(%) = SD\/meanX100\u003cbr\u003eIntra-Assay: CV\u0026lt;10%\u003cbr\u003eInter-Assay: CV\u0026lt;12%\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eLinearity\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSample\u003c\/td\u003e\n\u003ctd\u003e1:2\u003c\/td\u003e\n\u003ctd\u003e1:4\u003c\/td\u003e\n\u003ctd\u003e1:8\u003c\/td\u003e\n\u003ctd\u003e1:16\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eserum(n=5)\u003c\/td\u003e\n\u003ctd\u003e78-103%\u003c\/td\u003e\n\u003ctd\u003e94-103%\u003c\/td\u003e\n\u003ctd\u003e90-104%\u003c\/td\u003e\n\u003ctd\u003e91-105%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDTA plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e93-101%\u003c\/td\u003e\n\u003ctd\u003e87-102%\u003c\/td\u003e\n\u003ctd\u003e96-104%\u003c\/td\u003e\n\u003ctd\u003e97-105%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eheparin plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e95-105%\u003c\/td\u003e\n\u003ctd\u003e92-102%\u003c\/td\u003e\n\u003ctd\u003e98-105%\u003c\/td\u003e\n\u003ctd\u003e88-95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3\u003eStability\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.\u003cbr\u003eTo minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eReagents and materials provided\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"reagent_div\"\u003e\n\u003ctable class=\"reagent_table\"\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eQuantity\u003c\/td\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eQuantity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-coated, ready to use 96-well strip plate\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003ePlate sealer for 96 wells\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStandard\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003eStandard Diluent\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDetection Reagent A\u003c\/td\u003e\n\u003ctd\u003e1×120µL\u003c\/td\u003e\n\u003ctd\u003eAssay Diluent A\u003c\/td\u003e\n\u003ctd\u003e1×12mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDetection Reagent B\u003c\/td\u003e\n\u003ctd\u003e1×120µL\u003c\/td\u003e\n\u003ctd\u003eAssay Diluent B\u003c\/td\u003e\n\u003ctd\u003e1×12mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTMB Substrate\u003c\/td\u003e\n\u003ctd\u003e1×9mL\u003c\/td\u003e\n\u003ctd\u003eStop Solution\u003c\/td\u003e\n\u003ctd\u003e1×6mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWash Buffer (30 × concentrate)\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003ctd\u003eInstruction manual\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch3\u003eAssay procedure summary\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003e1. Prepare all reagents, samples and standards;\u003cbr\u003e2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;\u003cbr\u003e3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;\u003cbr\u003e4. Aspirate and wash 3 times;\u003cbr\u003e5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;\u003cbr\u003e6. Aspirate and wash 5 times;\u003cbr\u003e7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;\u003cbr\u003e8. Add 50µL Stop Solution. Read at 450nm immediately.\u003c\/p\u003e\n\u003cdiv class=\"product_reference\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd class=\"td_1\"\u003eMagazine\u003c\/td\u003e\n\u003ctd\u003eCitations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiological Trace Element Research\u003c\/td\u003e\n\u003ctd\u003eSynergistic Cardioprotective Effects of Combined Chromium Picolinate and Atorvastatin Treatment in Triton X-100-Induced Hyperlipidemia in Rats: Impact on Some Biochemical Markers\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28409410\" target=\"_blank\"\u003epubmed:28409410\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBASIC RESEARCH IN CARDIOLOGY\u003c\/td\u003e\n\u003ctd\u003eAutocrine effects of PCSK9 on cardiomyocytes\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33169229\/\" target=\"_blank\"\u003ePubmed: 33169229\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJ Transl Med\u003c\/td\u003e\n\u003ctd\u003eMulti-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33407555\" target=\"_blank\"\u003e33407555\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetabolism\u003c\/td\u003e\n\u003ctd\u003eMiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33775647\" target=\"_blank\"\u003e33775647\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEur Rev Med Pharmacol Sci\u003c\/td\u003e\n\u003ctd\u003eAssociation of serum proprotein convertase Subtilisin\/Kexin Type 9 (PCSK9) level with thyroid function disorders\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34533801\/\" target=\"_blank\"\u003e34533801\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClin Exp Hypertens\u003c\/td\u003e\n\u003ctd\u003eProprotein convertase subtilisin\/kexin type 9 is associated with atherosclerosis in patients with Behcet's disease\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35502687\/\" target=\"_blank\"\u003ePubmed:35502687\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product_relation\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd class=\"td_1\"\u003eCatalog No.\u003c\/td\u003e\n\u003ctd class=\"td_2\"\u003eRelated products for research use of Oryctolagus cuniculus (Rabbit) Organism species\u003c\/td\u003e\n\u003ctd class=\"td_3\"\u003eApplications (RESEARCH USE ONLY!)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEE189Rb\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/SEE189Rb.html\"\u003eELISA Kit for Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eEnzyme-linked immunosorbent assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLME189Rb\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/LME189Rb.html\"\u003eMagnetic Luminex Assay Kit for Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) ,etc.\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eMagnetic Luminex Assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Cloud-clone","offers":[{"title":"96T \/ The minimum detectable dose of this kit is typically less than 0.114ng\/mL \/ 0.312-20ng\/mL","offer_id":47582685430040,"sku":"SEE189Rb","price":760.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/products\/SE_BIG_046847d9-e3a9-4e12-9bf6-b46e4ddd44ee.jpg?v=1706138951","url":"https:\/\/danabiosci.com\/products\/new-product-633792","provider":"Dana Bioscience","version":"1.0","type":"link"}